CPB2, carboxypeptidase B2, 1361

N. diseases: 148; N. variants: 11
Disease: Venous Thromboembolism ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1861172
Disease: Venous Thromboembolism
Venous Thromboembolism 		0.040 AlteredExpression phenotype BEFREE Click to hear Ann Gil's presentation on new insights into thrombin activatable fibrinolysis inhibitor SUMMARY: Background Tissue factor pathway inhibitor (TFPI) regulates fibrin clot formation, and low TFPI plasma levels increase the risk of arterial thromboembolism and venous thromboembolism (VTE). 27490645 2016
CUI: C1861172
Disease: Venous Thromboembolism
Venous Thromboembolism 		0.040 GeneticVariation phenotype BEFREE Reported studies have showed that Thrombin Activatable Fibrinolysis Inhibitor (TAFI) may be associated with an increased risk of venous thromboembolism. 26071134 2015
CUI: C1861172
Disease: Venous Thromboembolism
Venous Thromboembolism 		0.040 GeneticVariation phenotype LHGDN Association between the Thr325Ile and Ala147Thr polymorphisms of the TAFI gene and the risk of venous thromboembolic disease. 18160566 2008
CUI: C1861172
Disease: Venous Thromboembolism
Venous Thromboembolism 		0.040 Biomarker phenotype LHGDN Adjusted for age, sex, other concomitant thrombophilic disorders and exogenous risk factors, the odds ratio for venous thromboembolism were 2.7 (0.8-8.7) for high factor VIII:C levels and 1.8 (0.6-5.3) for high TAFI levels. 12368162 2002
CUI: C1861172
Disease: Venous Thromboembolism
Venous Thromboembolism 		0.040 AlteredExpression phenotype BEFREE Adjusted for age, sex, other concomitant thrombophilic disorders and exogenous risk factors, the odds ratio for venous thromboembolism were 2.7 (0.8-8.7) for high factor VIII:C levels and 1.8 (0.6-5.3) for high TAFI levels. 12368162 2002